ST吉药(300108) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 196,716,998.45, a decline of 29.11% compared to the same period last year[7] - Net profit attributable to shareholders of the listed company was a loss of CNY 111,805,937.18, representing a decrease of 1,164.72% year-on-year[7] - Basic earnings per share were CNY -0.1679, a decrease of 962.66% year-on-year[7] - Total operating revenue for the current period is ¥196,716,998.45, a decrease of 29.1% from ¥277,486,002.97 in the previous period[39] - Operating profit for the current period is a loss of ¥117,301,563.49, compared to a loss of ¥4,090,081.49 in the previous period[41] - Net profit for the current period is a loss of ¥116,612,896.31, worsening from a loss of ¥10,550,814.91 in the previous period[41] - Total comprehensive income for the current period is a loss of ¥116,612,896.31, compared to a loss of ¥10,550,814.91 in the previous period[42] - The net profit for Q3 2020 was -206,130,118.79 CNY, compared to a net profit of 11,541,722.08 CNY in the same period last year, indicating a significant decline[49] - The operating profit for Q3 2020 was -200,894,770.26 CNY, a decrease from the operating profit of 23,682,504.25 CNY in Q3 2019[49] - The total profit for Q3 2020 was -205,054,324.58 CNY, compared to a profit of 23,479,253.67 CNY in Q3 2019[49] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,896,663,505.54, a decrease of 10.54% compared to the end of the previous year[7] - Current assets totaled CNY 1,040,250,716.23, down from CNY 1,337,935,968.32, indicating a decrease of about 22.19%[30] - The company's total equity decreased from CNY 410,571,504.28 to CNY 204,441,385.49, reflecting a decline of about 50.19%[34] - Total liabilities decreased from CNY 2,827,278,656.65 to CNY 2,692,222,120.05, a reduction of approximately 4.78%[32] - Short-term borrowings increased to CNY 908,020,756.87 from CNY 867,560,930.16, representing a rise of about 4.88%[32] - Long-term borrowings decreased from CNY 829,104,228.17 to CNY 781,932,836.32, indicating a reduction of about 5.71%[32] Cash Flow - The net cash flow from operating activities was a negative CNY 337,889.12, a decline of 100.73% compared to the previous year[7] - Cash inflow from operating activities was 629,689,609.80 CNY, down from 1,090,356,734.83 CNY in the same period last year, indicating a decrease of approximately 42.2%[56] - The cash inflow from operating activities was ¥56,913,249.79, a decrease from ¥416,197,045.42 in the previous period, reflecting reduced sales or service revenue[61] - The company reported a total cash outflow from investing activities of ¥15,889,061.51, leading to a net cash flow of -¥15,562,413.51 from investing activities[58] - The total cash inflow from financing activities was ¥512,605,359.72, while cash outflow was ¥342,186,517.90, resulting in a net cash flow of ¥170,418,841.82[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,519[11] - The largest shareholder, Lu Zhongkui, held 23.09% of the shares, amounting to 153,778,980 shares[11] Non-Recurring Items and Other Information - The company reported non-recurring gains and losses totaling CNY 3,877,819.06 for the reporting period[8] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[25] - There were no violations of external guarantees during the reporting period[24] - The company has not conducted any research, communication, or interview activities during the reporting period[26] - The company has committed to not transferring shares for 36 months post-IPO, and this commitment has been strictly adhered to[21] Cost and Expense Management - Operating costs decreased by 39.09% to ¥381,478,461.81 from ¥626,339,223.72 year-on-year, reflecting the decline in revenue[19] - Other income dropped by 79.09% to ¥9,356,706.73 from ¥44,747,987.30 year-on-year, due to a decrease in government subsidies received[19] - Income tax expenses decreased by 90.99% to ¥1,075,794.21 from ¥11,937,531.59 in the same period last year, attributed to a decline in total profit[20] - Financial expenses for the current period are ¥29,999,861.95, up from ¥23,846,761.58 in the previous period, primarily due to increased interest expenses[40] - Sales expenses amounted to 77,224,950.42 CNY, down from 85,266,993.27 CNY year-over-year, reflecting a reduction of approximately 9.5%[49] - Research and development expenses increased to ¥3,322,417.28 from ¥528,940.72, reflecting a significant investment in innovation[40] - Research and development expenses were 10,269,927.57 CNY, slightly decreased from 10,325,124.95 CNY in the previous year[49]